Cargando…

Clinical use, efficacy, and durability of maraviroc for antiretroviral therapy in routine care: A European survey

OBJECTIVES: The study aimed to survey maraviroc use and assess effectiveness and durability of maraviroc-containing antiretroviral treatment (ART) in routine practice across Europe. METHODS: Data were retrieved from 26 cohorts in 8 countries comprising adults who started maraviroc in 2005–2016 and h...

Descripción completa

Detalles Bibliográficos
Autores principales:	De Luca, Andrea, Pezzotti, Patrizio, Boucher, Charles, Döring, Matthias, Incardona, Francesca, Kaiser, Rolf, Lengauer, Thomas, Pfeifer, Nico, Schülter, Eugen, Vandamme, Anne-Mieke, Zazzi, Maurizio, Geretti, Anna Maria
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6874206/ https://www.ncbi.nlm.nih.gov/pubmed/31751385 http://dx.doi.org/10.1371/journal.pone.0225381

Ejemplares similares

Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models
por: Prosperi, Mattia C. F., et al.
Publicado: (2010)

Correction: Antiretroviral Therapy Optimisation without Genotype Resistance Testing: A Perspective on Treatment History Based Models
por: Prosperi, Mattia C. F., et al.
Publicado: (2011)

Selecting anti-HIV therapies based on a variety of genomic and clinical factors
por: Rosen-Zvi, Michal, et al.
Publicado: (2008)

Comparison of Classifier Fusion Methods for Predicting Response to Anti HIV-1 Therapy
por: Altmann, André, et al.
Publicado: (2008)

Time on drug analysis based on real life data
por: Schülter, Eugen, et al.
Publicado: (2014)

Using drug exposure for predicting drug resistance – A data-driven genotypic interpretation tool
por: Pironti, Alejandro, et al.
Publicado: (2017)

Cohort Profile: A European Multidisciplinary Network for the Fight against HIV Drug Resistance (EuResist Network)
por: Rossetti, Barbara, et al.
Publicado: (2023)

Durability and Effectiveness of Maraviroc-Containing Regimens in HIV-1-Infected Individuals with Virological Failure in Routine Clinical Practice
por: Potard, Valérie, et al.
Publicado: (2015)

The EuResist expert model for customised HAART optimisation: 2010 update and extension to newest compounds
por: Pironti, A, et al.
Publicado: (2010)

Determination of Phenotypic Resistance Cutoffs From Routine Clinical Data
por: Pironti, Alejandro, et al.
Publicado: (2017)

Only Slight Impact of Predicted Replicative Capacity for Therapy Response Prediction
por: Weisser, Hendrik, et al.
Publicado: (2010)

Maraviroc in treatment-experienced patients with HIV-1 infection - experience from routine clinical practice
por: Reuter, S, et al.
Publicado: (2010)

Parameters Influencing Baseline HIV-1 Genotypic Tropism Testing Related to Clinical Outcome in Patients on Maraviroc
por: Sierra, Saleta, et al.
Publicado: (2015)

Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodes
por: Rhee, Soo-Yon, et al.
Publicado: (2012)

Improved therapy-success prediction with GSS estimated from clinical HIV-1 sequences
por: Pironti, Alejandro, et al.
Publicado: (2014)

A genotypic method for determining HIV-2 coreceptor usage enables epidemiological studies and clinical decision support
por: Döring, Matthias, et al.
Publicado: (2016)

Pre‐existing singleton E138A mutations in the reverse transcriptase gene do not affect the efficacy of first‐line antiretroviral therapy regimens using rilpivirine in human immunodeficiency virus‐infected patients
por: Kuznetsova, Anna, et al.
Publicado: (2022)

Maraviroc in the treatment of HIV infection
por: Ray, Neelanjana
Publicado: (2009)

Prolonged administration of maraviroc reactivates latent HIV in vivo but it does not prevent antiretroviral-free viral rebound
por: López-Huertas, María Rosa, et al.
Publicado: (2020)

Drug resistance testing through remote genotyping and predicted treatment options in human immunodeficiency virus type 1 infected Tanzanian subjects failing first or second line antiretroviral therapy
por: Svärd, Jenny, et al.
Publicado: (2017)

geno2pheno[ngs-freq]: a genotypic interpretation system for identifying viral drug resistance using next-generation sequencing data
por: Döring, Matthias, et al.
Publicado: (2018)

Clinical Evaluation of Rega 8: An Updated Genotypic Interpretation System That Significantly Predicts HIV-Therapy Response
por: Vercauteren, Jurgen, et al.
Publicado: (2013)

Superinfection with drug-resistant HIV is rare and does not contribute substantially to therapy failure in a large European cohort
por: Bartha, István, et al.
Publicado: (2013)

Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort study
por: Jesús Pérez Elías, María, et al.
Publicado: (2014)

Switch to maraviroc with darunavir/r, both QD, in patients with suppressed HIV-1 was well tolerated but virologically inferior to standard antiretroviral therapy: 48-week results of a randomized trial
por: Rossetti, Barbara, et al.
Publicado: (2017)

Improving HIV coreceptor usage prediction in the clinic using hints from next-generation sequencing data
por: Pfeifer, Nico, et al.
Publicado: (2012)

Determinants of HIV-1 Late Presentation in Patients Followed in Europe
por: Miranda, Mafalda N. S., et al.
Publicado: (2021)

Maraviroc: the evidence for its potential in the management of HIV
por: Profit, Louise
Publicado: (2007)

Comparison of phenotypic and genotypic tropism determination in triple-class-experienced HIV patients eligible for maraviroc treatment
por: Vandekerckhove, Linos, et al.
Publicado: (2011)

Short-term maraviroc exposure, a clinical approach to decide on maraviroc prescription in HIV-1-infected treatment-naïve patients
por: Gonzalez-Serna, Alejandro, et al.
Publicado: (2016)

Efficacy and safety of an NRTI-sparing regimen in antiretroviral-naïve HIV-infected patients: once-daily maraviroc plus lopinavir/ritonavir
por: Nozza, S, et al.
Publicado: (2010)

The utility of maraviroc, an antiretroviral agent used to treat HIV, as treatment for opioid abuse? Data from MRI and behavioural testing in rats
por: Iriah, Sade C., et al.
Publicado: (2021)

Impact of antiretroviral therapy intensification with C-C motif chemokine receptor 5 antagonist maraviroc on HIV-associated neurocognitive impairment
por: Shikuma, Cecilia M., et al.
Publicado: (2023)

Association Between HIV-1 Coreceptor Usage and Resistance to Broadly Neutralizing Antibodies
por: Pfeifer, Nico, et al.
Publicado: (2014)

Family-Joining: A Fast Distance-Based Method for Constructing Generally Labeled Trees
por: Kalaghatgi, Prabhav, et al.
Publicado: (2016)

Corrigendum to: Family-joining: A fast distance-based method for constructing generally labeled trees
por: Kalaghatgi, Prabhav, et al.
Publicado: (2020)

Implications of maraviroc and/or rapamycin in a mouse model of fragility
por: Pérez-Martínez, Laura, et al.
Publicado: (2020)

Trends of Transmitted and Acquired Drug Resistance in Europe From 1981 to 2019: A Comparison Between the Populations of Late Presenters and Non-late Presenters
por: Miranda, Mafalda N. S., et al.
Publicado: (2022)

Intensifying Antiretroviral Therapy With Raltegravir and Maraviroc During Early Human Immunodeficiency Virus (HIV) Infection Does Not Accelerate HIV Reservoir Reduction
por: Ostrowski, Mario, et al.
Publicado: (2015)

Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc
por: Borm, Katharina, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_tubo3h0qr94743cb3nb5bobdok